Phylicia Aaron

495 total citations
20 papers, 285 citations indexed

About

Phylicia Aaron is a scholar working on Oncology, Reproductive Medicine and Molecular Biology. According to data from OpenAlex, Phylicia Aaron has authored 20 papers receiving a total of 285 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Oncology, 7 papers in Reproductive Medicine and 6 papers in Molecular Biology. Recurrent topics in Phylicia Aaron's work include PARP inhibition in cancer therapy (8 papers), Ovarian cancer diagnosis and treatment (7 papers) and Cancer Immunotherapy and Biomarkers (5 papers). Phylicia Aaron is often cited by papers focused on PARP inhibition in cancer therapy (8 papers), Ovarian cancer diagnosis and treatment (7 papers) and Cancer Immunotherapy and Biomarkers (5 papers). Phylicia Aaron collaborates with scholars based in United States and Qatar. Phylicia Aaron's co-authors include Angie Gelli, John Nemunaitis, Laura Stanbery, Luisa Manning, Mantana Jamklang, Ernest Bognar, Gladice Wallraven, Staci Horvath, Rodney P. Rocconi and Kiem Vu and has published in prestigious journals such as Journal of Clinical Oncology, Antimicrobial Agents and Chemotherapy and Gynecologic Oncology.

In The Last Decade

Phylicia Aaron

20 papers receiving 278 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Phylicia Aaron United States	11	159	104	80	66	49	20	285
Suzanne Dowson United Kingdom	7	177 1.1×	100 1.0×	170 2.1×	77 1.2×	15 0.3×	11	348
Yudith Ramos Valdés Canada	12	190 1.2×	50 0.5×	256 3.2×	72 1.1×	115 2.3×	21	462
Malcolm Farquharson United Kingdom	3	138 0.9×	88 0.8×	112 1.4×	56 0.8×	7 0.1×	6	255
Dimitra Stefanou Greece	11	92 0.6×	38 0.4×	123 1.5×	13 0.2×	12 0.2×	29	310
Nasim Kheshtchin Iran	9	151 0.9×	255 2.5×	189 2.4×	18 0.3×	23 0.5×	16	479
Nayara Gusmão Tessarollo Brazil	8	83 0.5×	36 0.3×	120 1.5×	20 0.3×	25 0.5×	16	241
Unnati M. Pandya United States	10	41 0.3×	28 0.3×	159 2.0×	15 0.2×	88 1.8×	11	261
Martina Magni Italy	10	136 0.9×	64 0.6×	144 1.8×	3 0.0×	25 0.5×	19	324
Julianna S. Deakyne United States	10	168 1.1×	61 0.6×	173 2.2×	4 0.1×	50 1.0×	13	361

Countries citing papers authored by Phylicia Aaron

Since Specialization

Citations

This map shows the geographic impact of Phylicia Aaron's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Phylicia Aaron with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Phylicia Aaron more than expected).

Fields of papers citing papers by Phylicia Aaron

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Phylicia Aaron. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Phylicia Aaron. The network helps show where Phylicia Aaron may publish in the future.

Co-authorship network of co-authors of Phylicia Aaron

This figure shows the co-authorship network connecting the top 25 collaborators of Phylicia Aaron. A scholar is included among the top collaborators of Phylicia Aaron based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Phylicia Aaron. Phylicia Aaron is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Barve, Minal, Phylicia Aaron, Luisa Manning, et al.. (2022). Pilot Study of Combination Gemogenovatucel-T (Vigil) and Durvalumab in Women With Relapsed BRCA-wt Triple-Negative Breast or Ovarian Cancer. Clinical Medicine Insights Oncology. 16. 1363231461–1363231461. 15 indexed citations

Rocconi, Rodney P., Bradley J. Monk, Thomas J. Herzog, et al.. (2021). Gemogenovatucel-T (Vigil) immunotherapy demonstrates clinical benefit in homologous recombination proficient (HRP) ovarian cancer. Gynecologic Oncology. 161(3). 676–680. 26 indexed citations

Rocconi, Rodney P., Bradley J. Monk, Thomas J. Herzog, et al.. (2021). Gemogenovatucel-T (Vigil) maintenance immunotherapy: 3-year survival benefit in homologous recombination proficient (HRP) ovarian cancer. Gynecologic Oncology. 163(3). 459–464. 14 indexed citations

Morand, Susan, Khalil Choucair, David Willoughby, et al.. (2021). Network based analysis identifies TP53m-BRCA1/2wt-homologous recombination proficient (HRP) population with enhanced susceptibility to Vigil immunotherapy. Cancer Gene Therapy. 29(7). 993–1000. 5 indexed citations

Rocconi, Rodney P., Erin Stevens, Justin Bottsford-Miller, et al.. (2021). Proof of principle study of sequential combination atezolizumab and Vigil in relapsed ovarian cancer. Cancer Gene Therapy. 29(3-4). 369–382. 20 indexed citations

Rocconi, Rodney P., Laura Stanbery, Luciana Madeira da Silva, et al.. (2021). Long-Term Follow-Up of Gemogenovatucel-T (Vigil) Survival and Molecular Signals of Immune Response in Recurrent Ovarian Cancer. Vaccines. 9(8). 894–894. 12 indexed citations

Rocconi, Rodney P., Sharad Ghamande, Minal Barve, et al.. (2021). Maintenance vigil immunotherapy in newly diagnosed advanced ovarian cancer: Efficacy assessment of homologous recombination proficient (HRP) patients in the phase IIb VITAL trial.. Journal of Clinical Oncology. 39(15_suppl). 5502–5502. 4 indexed citations

Morand, Susan, Rachel Royfman, Monika Devanaboyina, et al.. (2020). Current Ovarian Cancer Maintenance Strategies and Promising New Developments. Journal of Cancer. 12(1). 38–53. 47 indexed citations

Rocconi, Rodney P., Erin Stevens, Justin Bottsford-Miller, et al.. (2020). A phase I combination study of vigil and atezolizumab in recurrent/refractory advanced-stage ovarian cancer: Efficacy assessment in BRCA1/2-wt patients.. Journal of Clinical Oncology. 38(15_suppl). 3002–3002. 10 indexed citations

10.

Rocconi, Rodney P., Elizabeth A. Grosen, Sharad Ghamande, et al.. (2020). Randomized double-blind placebo-controlled trial of primary maintenance vigil immunotherapy (VITAL study) in stage III/IV ovarian cancer: Efficacy assessment in BRCA1/2-wt patients.. Journal of Clinical Oncology. 38(15_suppl). 6017–6017. 3 indexed citations

11.

Oh, Jonathan, Minal Barve, Neil Senzer, et al.. (2020). Long-term follow-up of Phase 2A trial results involving advanced ovarian cancer patients treated with Vigil® in frontline maintenance. Gynecologic Oncology Reports. 34. 100648–100648. 19 indexed citations

12.

Aaron, Phylicia, Kiem Vu, & Angie Gelli. (2020). An Antivirulence Approach for Preventing Cryptococcus neoformans from Crossing the Blood-Brain Barrier via Novel Natural Product Inhibitors of a Fungal Metalloprotease. mBio. 11(4). 18 indexed citations

13.

Austin, Jared P., Christine Cassidy, Laura Stanbery, et al.. (2020). Cancer Healthcare Utilization Impact of Precision Therapeutics: Hospitalization/Emergency Visits. 3(3). 3 indexed citations

14.

Rocconi, Rodney P., John K. Chan, Minal Barve, et al.. (2020). Randomized double-blind placebo-controlled trial of primary maintenance vigil immunotherapy (VITAL study) in stage III/IV ovarian cancer: Efficacy assessment in BRCA1/2-wt patients. Gynecologic Oncology. 159. 51–52. 3 indexed citations

15.

Rocconi, Rodney P., Sharad Ghamande, John K. Chan, et al.. (2020). 15 Randomized double-blind placebo controlled trial of frontline maintenance vigil immunotherapy (VITAL study) in stage III/IV ovarian cancer: efficacy assessment in BRCA1/2-wt patients. A11–A12. 1 indexed citations

16.

Herron, James N., Laura Stanbery, Phylicia Aaron, et al.. (2020). Vigil: Personalized Immunotherapy Generating Systemic Cytotoxic T Cell Response. 3(4). 14 indexed citations

17.

Aaron, Phylicia & Angie Gelli. (2019). Harnessing the Activity of the Fungal Metalloprotease, Mpr1, To Promote Crossing of Nanocarriers through the Blood–Brain Barrier. ACS Infectious Diseases. 6(1). 138–149. 12 indexed citations

18.

Thompson, George R., Charles R. Krois, Verena K. Affolter, et al.. (2018). Examination of Fluconazole-Induced Alopecia in an Animal Model and Human Cohort. Antimicrobial Agents and Chemotherapy. 63(2). 7 indexed citations

19.

Aaron, Phylicia, et al.. (2017). The blood-brain barrier internalisesCryptococcus neoformansvia the EphA2-tyrosine kinase receptor. Cellular Microbiology. 20(3). e12811–e12811. 51 indexed citations

20.

Aaron, Phylicia, et al.. (1994). A case of Fabry disease (alpha-galactosidase A deficiency).. PubMed. 92(6). 222–6. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact